Eiger BioPharmaceuticals, Inc.
OTC: EIGRQ0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- David Apelian
- Employees
- 25
- Headquarters
- Palo Alto, United States
- IPO year
- 2014
- Market cap
- $12.6M
- Website
- https://www.eigerbio.com
Loading EIGRQ…
Loading profile data…Frequently asked questions about EIGRQ
What does Eiger BioPharmaceuticals, Inc. (EIGRQ) do?
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical firm dedicated to discovering and advancing treatments for critical health issues, particularly hepatitis delta virus (HDV), among other severe diseases. The company's marketed product, Zokinvy, is prescribed for patients suffering from Hutchinson-Gilford progeria syndrome an...
Where does EIGRQ trade?
Eiger BioPharmaceuticals, Inc. (EIGRQ) trades on the Other OTC.
What sector is EIGRQ in?
Eiger BioPharmaceuticals, Inc. (EIGRQ) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Eiger BioPharmaceuticals, Inc.?
David Apelian is the chief executive officer of Eiger BioPharmaceuticals, Inc. (EIGRQ).
Where is Eiger BioPharmaceuticals, Inc. headquartered?
Eiger BioPharmaceuticals, Inc. is headquartered in United States.
Does EIGRQ pay a dividend?
Eiger BioPharmaceuticals, Inc. (EIGRQ) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did EIGRQ go public?
Eiger BioPharmaceuticals, Inc. (EIGRQ) completed its initial public offering in 2014.